NCT04839991 - Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

July 25, 2024

Study Completion Date

September 25, 2024

Conditions

Advanced and/or Metastatic Solid Tumours

Interventions

DRUG

CB307

Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin

Trial Locations (20)

28027

RECRUITING

Clinica Universidad de Navarra, Madrid

28040

RECRUITING

HU Fundacion Jimenez Diaz, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28050

RECRUITING

Hospital Universitario HM Sanchinarro, Madrid

RECRUITING

NEXT Oncology Hospital Quironsalud Madrid, Madrid

30120

RECRUITING

HU Virgen de la Arrixaca, Murcia

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

41013

RECRUITING

HU Virgen del Rocio - PPDS, Seville

98109-5311

RECRUITING

University of Washington, Seattle

1066 CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

1081 HV

WITHDRAWN

VUMC Research B.V, Amsterdam

P.O. Box 30 001

RECRUITING

University Medical Center Groningen,, Groningen

Unknown

RECRUITING

Erasmus University Medical Center Rotterdam, Rotterdam

3584 CX

RECRUITING

UMC Utrecht Cancer Center, Utrecht

08036

RECRUITING

hospital clinic de Barcelona, Barcelona

08041

RECRUITING

hospital de la Sanat Creu i Sant Pau, Barcelona

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

SM2 5PT

RECRUITING

Royal Marsden Hospital, London

NW1 2BU

RECRUITING

University College London Hospitals NHS Foundation Trust, London

W1G 6AD

RECRUITING

Sarah Cannon Research Institute, UK, London